What's the most recent regulatory action in Left ventricular cardiac dysfunction?

Most recent: Diovan — FDA approved.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/left-ventricular-cardiac-dysfunction.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Left ventricular cardiac dysfunction — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Left ventricular cardiac dysfunction (disease) competitive landscape: 8 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

8 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Left ventricular cardiac dysfunction, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Diovan	VALSARTAN	Novartis	Angiotensin 2 Receptor Blocker [EPC]	Type-1 angiotensin II receptor	1996-01-01
Coreg	CARVEDILOL	Waylis	alpha-Adrenergic Blocker [EPC]	Beta-2 adrenergic receptor	1995-01-01
Altace	RAMIPRIL	King Pfizer	Angiotensin Converting Enzyme Inhibitor [EPC]	Angiotensin-converting enzyme	1991-01-01
Nitroglycerin	glyceryl trinitrate	Fougera	Nitrate Vasodilator [EPC]	guanylate cyclase	1981-01-01
Capozide 25/15	CAPTOPRIL	Aarxion Anda Hlding	Thiazide Diuretic [EPC]	Renin	1981-01-01
Mavik	Mavik	Dr. Reddy's Laboratories Limited		Angiotensin-converting enzyme
nitroglycerine	nitroglycerine	University Hospital, Ghent		Atrial natriuretic peptide receptor 1, Soluble guanylate cyclase
Diovan	Diovan	Bayer		Platelet glycoprotein VI, Type-1 angiotensin II receptor, Angiotensin II receptor (AT-1) type-1

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

2026-04-21 — Diovan · FDA · approved · US

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Aarxion Anda Hlding · 1 drug in Left ventricular cardiac dysfunction
Bayer · 1 drug in Left ventricular cardiac dysfunction
Dr. Reddy's Laboratories Limited · 1 drug in Left ventricular cardiac dysfunction
Fougera · 1 drug in Left ventricular cardiac dysfunction
King Pfizer · 1 drug in Left ventricular cardiac dysfunction
Novartis · 1 drug in Left ventricular cardiac dysfunction
University Hospital, Ghent · 1 drug in Left ventricular cardiac dysfunction
Waylis · 1 drug in Left ventricular cardiac dysfunction

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Left ventricular cardiac dysfunction:

Cite this brief

Drug Landscape (2026). Left ventricular cardiac dysfunction — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/left-ventricular-cardiac-dysfunction. Accessed 2026-06-10.

Left ventricular cardiac dysfunction full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing